Eli Lilly’s big GLP-1 investment — plus, what we want from 4 portfolio stock earnings

Health, Fitness & Food

Products You May Like

Articles You May Like

Neuralink competitor Paradromics secures investment from Saudi Arabia’s Neom
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Healthy Returns: Ozempic helps curb alcohol use in new study — and doctors are concerned about telehealth GLP-1s
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short 
What Does Your Perfect Run Feel Like? The ForeverRun NITRO™ 2 Might Just Be the Answer

Leave a Reply

Your email address will not be published. Required fields are marked *